These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35648810)

  • 1. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q.
    Spurrier J; Nicholson L; Fang XT; Stoner AJ; Toyonaga T; Holden D; Siegert TR; Laird W; Allnutt MA; Chiasseu M; Brody AH; Takahashi H; Nies SH; Pérez-Cañamás A; Sadasivam P; Lee S; Li S; Zhang L; Huang YH; Carson RE; Cai Z; Strittmatter SM
    Sci Transl Med; 2022 Jun; 14(647):eabi8593. PubMed ID: 35648810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal transcriptome, tau and synapse loss in Alzheimer's knock-in mice require prion protein.
    Stoner A; Fu L; Nicholson L; Zheng C; Toyonaga T; Spurrier J; Laird W; Cai Z; Strittmatter SM
    Alzheimers Res Ther; 2023 Nov; 15(1):201. PubMed ID: 37968719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes.
    Haas LT; Salazar SV; Smith LM; Zhao HR; Cox TO; Herber CS; Degnan AP; Balakrishnan A; Macor JE; Albright CF; Strittmatter SM
    Cell Rep; 2017 Jul; 20(1):76-88. PubMed ID: 28683325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment.
    Wang J; Huang Q; He K; Li J; Guo T; Yang Y; Lin Z; Li S; Vanderlinden G; Huang Y; Van Laere K; Guan Y; Guo Q; Ni R; Li B; Xie F
    Alzheimers Dement; 2024 Jun; 20(6):3876-3888. PubMed ID: 38634334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of mGluR1 Mediates C1q-Dependent Microglial Phagocytosis of Glutamatergic Synapses in Alzheimer's Rodent Models.
    Bie B; Wu J; Foss JF; Naguib M
    Mol Neurobiol; 2019 Aug; 56(8):5568-5585. PubMed ID: 30652266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models.
    Abd-Elrahman KS; Hamilton A; Vasefi M; Ferguson SSG
    Mol Brain; 2018 Apr; 11(1):19. PubMed ID: 29631635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.
    Carpanini SM; Torvell M; Bevan RJ; Byrne RAJ; Daskoulidou N; Saito T; Saido TC; Taylor PR; Hughes TR; Zelek WM; Morgan BP
    Acta Neuropathol Commun; 2022 Jul; 10(1):99. PubMed ID: 35794654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid Fibril-Induced Astrocytic Glutamate Transporter Disruption Contributes to Complement C1q-Mediated Microglial Pruning of Glutamatergic Synapses.
    Wu J; Bie B; Foss JF; Naguib M
    Mol Neurobiol; 2020 May; 57(5):2290-2300. PubMed ID: 32008166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periodontal Infection Aggravates C1q-Mediated Microglial Activation and Synapse Pruning in Alzheimer's Mice.
    Hao X; Li Z; Li W; Katz J; Michalek SM; Barnum SR; Pozzo-Miller L; Saito T; Saido TC; Wang Q; Roberson ED; Zhang P
    Front Immunol; 2022; 13():816640. PubMed ID: 35178049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knock-in models related to Alzheimer's disease: synaptic transmission, plaques and the role of microglia.
    Benitez DP; Jiang S; Wood J; Wang R; Hall CM; Peerboom C; Wong N; Stringer KM; Vitanova KS; Smith VC; Joshi D; Saito T; Saido TC; Hardy J; Hanrieder J; De Strooper B; Salih DA; Tripathi T; Edwards FA; Cummings DM
    Mol Neurodegener; 2021 Jul; 16(1):47. PubMed ID: 34266459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies.
    Dejanovic B; Huntley MA; De Mazière A; Meilandt WJ; Wu T; Srinivasan K; Jiang Z; Gandham V; Friedman BA; Ngu H; Foreman O; Carano RAD; Chih B; Klumperman J; Bakalarski C; Hanson JE; Sheng M
    Neuron; 2018 Dec; 100(6):1322-1336.e7. PubMed ID: 30392797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the relationship between synaptic density and metabotropic glutamate receptors in early Alzheimer's disease: a multi-tracer PET study.
    Salardini E; O'Dell RS; Tchorz E; Nabulsi NB; Huang Y; Carson RE; van Dyck CH; Mecca AP
    bioRxiv; 2024 Sep; ():. PubMed ID: 39386453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncanonical Metabotropic Glutamate Receptor 5 Signaling in Alzheimer's Disease.
    Abd-Elrahman KS; Ferguson SSG
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():235-254. PubMed ID: 34516293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synaptic mitochondrial dysfunction and septin accumulation are linked to complement-mediated synapse loss in an Alzheimer's disease animal model.
    Györffy BA; Tóth V; Török G; Gulyássy P; Kovács RÁ; Vadászi H; Micsonai A; Tóth ME; Sántha M; Homolya L; Drahos L; Juhász G; Kékesi KA; Kardos J
    Cell Mol Life Sci; 2020 Dec; 77(24):5243-5258. PubMed ID: 32034429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Synaptic Density Imaging with
    Toyonaga T; Smith LM; Finnema SJ; Gallezot JD; Naganawa M; Bini J; Mulnix T; Cai Z; Ropchan J; Huang Y; Strittmatter SM; Carson RE
    J Nucl Med; 2019 Dec; 60(12):1780-1786. PubMed ID: 31101744
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease.
    Hamilton A; Esseltine JL; DeVries RA; Cregan SP; Ferguson SS
    Mol Brain; 2014 May; 7():40. PubMed ID: 24886239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model.
    Hamilton A; Vasefi M; Vander Tuin C; McQuaid RJ; Anisman H; Ferguson SS
    Cell Rep; 2016 May; 15(9):1859-65. PubMed ID: 27210751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aβ pathology downregulates brain mGluR5 density in a mouse model of Alzheimer.
    Lee M; Lee HJ; Park IS; Park JA; Kwon YJ; Ryu YH; Kim CH; Kang JH; Hyun IY; Lee KC; Choi JY
    Neuropharmacology; 2018 May; 133():512-517. PubMed ID: 29427650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligomers of Amyloid β Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease.
    Haas LT; Strittmatter SM
    J Biol Chem; 2016 Aug; 291(33):17112-21. PubMed ID: 27325698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease.
    Bellozi PMQ; Gomes GF; da Silva MCM; Lima IVA; Batista CRÁ; Carneiro Junior WO; Dória JG; Vieira ÉLM; Vieira RP; de Freitas RP; Ferreira CN; Candelario-Jalil E; Wyss-Coray T; Ribeiro FM; de Oliveira ACP
    Neuropharmacology; 2019 Dec; 160():107785. PubMed ID: 31541651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.